Education
About Us
Working with TipRanks
Follow Us
AddLife AB Class B (SE:ALIF.B)
:ALIF.B
Top Page
AddLife AB
(OTC:ALIF.B)
69Neutral
AddLife AB (ALIF.B) vs. S&P 500 (SPY)
Market Cap
$23.22B
Dividend Yield0.24%
Average Volume (3M)196.97K
Price to Earnings (P/E)75.1
Beta (1Y)0.91
Revenue Growth6.33%
EPS Growth291.12%
CountrySE
Employees2,251
SectorHealthcare
Sector Strength48
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.76
Shares Outstanding117,877,460
10 Day Avg. Volume250,109
30 Day Avg. Volume196,967
Financial Highlights & Ratios
PEG Ratio3.28
Price to Book (P/B)4.50
Price to Sales (P/S)0.00
P/FCF Ratio19.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$178.04Price Target Upside-4.69% Downside
Rating ConsensusHold
Number of Analyst Covering1
AddLife AB Business Overview & Revenue Model
Company DescriptionAddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments segments. This segment also offers support, maintenance, advice, and training services. The Medtech segment provides medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, fall prevention, welfare technology, ear, and nose and throat segments, as well as bathroom-related assistive devices and assistive devices for children with disabilities. It operates in Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.
How the Company Makes MoneyAddLife AB generates revenue primarily through the sale and distribution of medical and laboratory equipment to healthcare providers, laboratories, and research institutions. This includes a wide range of products such as diagnostic instruments, medical devices, and laboratory supplies. The company works closely with leading manufacturers and suppliers in the life sciences industry to offer a diverse and high-quality product portfolio. Revenue streams include direct sales to customers, long-term supply contracts, and service agreements for equipment maintenance and support. Significant partnerships with healthcare providers and research institutions, as well as a strong presence in the European market, contribute to its earnings by ensuring a steady demand for its products and services.
AddLife AB Financial Statement Overview
Summary
AddLife AB demonstrates solid financial health across its income statement, balance sheet, and cash flow statements. The company has achieved strong revenue and cash flow growth, reduced its financial leverage, and maintained profitability. While operational margins have faced slight pressure, the overall financial standing is strong with significant potential for future growth.Income Statement
AddLife AB shows strong revenue growth with a significant increase from 2023 to 2024. The gross profit margin is healthy, consistently above 35%. However, the EBIT margin has decreased slightly over the last few years, indicating slight pressure on operational efficiency. The company maintains a solid net profit margin, reflecting overall profitability.85
Very Positive
Balance Sheet
The balance sheet is robust with zero total debt in 2024, resulting in a strong equity position. The debt-to-equity ratio has improved significantly, indicating reduced financial leverage and potential risk. The equity ratio remains stable, showcasing a sound financial structure. However, the company should be cautious of any future liabilities that may arise.75
Positive
Cash Flow
Cash flow from operations has shown impressive growth, indicating strong operational cash generation. The free cash flow growth is substantial, highlighting efficient capital expenditure management. The operating cash flow to net income ratio is favorable, suggesting good cash conversion from profits. These factors contribute to a positive cash flow outlook.80
Positive
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 10.42B | 10.29B | 9.69B | 9.08B | 7.99B | 5.27B | Gross Profit |
| 3.92B | 3.86B | 3.60B | 3.43B | 2.86B | 1.82B | EBIT |
| 770.00M | 721.00M | 585.00M | 808.00M | 996.30M | 672.50M | EBITDA |
| 968.00M | 1.52B | 1.55B | 1.45B | 1.46B | 951.00M | Net Income Common Stockholders |
| 309.00M | 252.00M | 190.00M | 480.00M | 719.00M | 517.80M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 280.00M | 331.00M | 272.00M | 376.00M | 345.30M | 216.00M | Total Assets |
| 13.26B | 13.05B | 12.74B | 13.06B | 10.60B | 4.15B | Total Debt |
| 5.54B | 5.07B | 5.29B | 5.59B | 4.10B | 805.80M | Net Debt |
| 5.26B | 4.74B | 5.02B | 5.21B | 3.76B | 589.80M | Total Liabilities |
| 8.10B | 7.75B | 7.79B | 8.09B | 6.30B | 2.26B | Stockholders Equity |
| 5.16B | 5.31B | 4.96B | 4.97B | 4.29B | 1.88B |
| Cash Flow | Free Cash Flow | ||||
| 1.12B | 798.00M | 465.00M | 627.00M | 866.30M | 857.90M | Operating Cash Flow |
| 1.24B | 1.09B | 773.00M | 909.00M | 1.01B | 950.10M | Investing Cash Flow |
| -395.00M | -386.00M | -317.00M | -1.09B | -2.98B | -428.70M | Financing Cash Flow |
| -682.00M | -682.00M | -554.00M | 134.00M | 2.07B | -372.50M |
AddLife AB Technical Analysis
Positive
186.80
Price Trends
157.53
Positive
153.72
Positive
151.16
Positive
Market Momentum
10.41
Negative
69.57
Neutral
79.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALIF.B, the sentiment is Positive. The current price of 186.8 is above the 20-day moving average (MA) of 170.76, above the 50-day MA of 157.53, and above the 200-day MA of 151.16, indicating a bullish trend. The MACD of 10.41 indicates Negative momentum. The RSI at 69.57 is Neutral, neither overbought nor oversold. The STOCH value of 79.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ALIF.B.
AddLife AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Performance Comparison
SE:ALIF.B
AddLife AB
190.40
79.84
72.22%
GB:0O5H
Elekta AB
51.85
-27.43
-34.60%
GB:0YAY
Vitrolife AB
159.84
-15.13
-8.65%
BITGF
Biotage AB
9.48
-6.06
-39.00%
BOEUF
BONESUPPORT HOLDING AB
29.08
7.54
35.00%
DE:0V0
Vimian Group AB
3.58
0.66
22.60%
AddLife AB Earnings Call Summary
Earnings Call Date:Apr 25, 2025
(Q3-2024)
| % Change Since: 19.23%|
Next Earnings Date:Jul 15, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook with stable organic growth and positive developments such as the acquisition of BonsaiLab and improved Medtech margins. However, challenges in the Labtech segment and key markets, as well as currency impacts, were notable concerns.Q3-2024 Updates
Positive Updates
Organic Growth
The company achieved a 3% organic growth in both Labtech and Medtech segments.
Stable Cash Flow
Operating cash flow remained stable compared to last year, with improved cash conversion due to focus on inventory reduction and working capital efficiency.
Acquisition of BonsaiLab
The acquisition of BonsaiLab, a leading Spanish distributor in cell and molecular biology, was completed, contributing positively to the company's growth.
Medtech Margin Improvement
The EBITA margin in the Medtech segment increased by 7%, reaching 10.7% compared to 10% in the previous year.
Profitability Improvement Initiatives
The profitability improvement initiatives, including the closure of Camanio, are progressing according to plan, resulting in significant cost savings.
Negative Updates
Weak Labtech Instrument Sales
The Labtech segment experienced a weakness in demand for advanced high-margin instruments, leading to a lower margin of 8.9%.
Challenges in Key Markets
The U.K. and Swedish markets faced challenges due to strikes and staffing shortages, impacting sales and growth.
Slow New Product Launches
Some new product launches have been slower than expected, affecting sales targets.
Currency Impact
Currency had a negative impact of minus 3% on growth.
Company Guidance
In the third quarter of 2024, AddLife reported a 3% organic and currency-adjusted growth, maintaining a stable EBITA margin of 9.8%, despite the typically slower summer months. The company's Labtech segment experienced a slight decline in instrument sales, although consumable sales remained stable. In contrast, the Medtech segment also recorded a 3% growth, driven by higher-margin product sales and ongoing profitability improvement initiatives. Operational cash flow was stable, with a focus on inventory reduction and working capital efficiency, despite a SEK 73 million negative impact from decreased accounts payables. The acquisition of BonsaiLab contributed to the group's positive performance, bringing strong market conditions and healthy margins. Net debt remained unchanged, supported by favorable foreign exchange impacts, maintaining a leverage ratio of 3.6. The company remains committed to its established priorities of enhancing profit margins, organic growth, and strategic acquisitions while anticipating a seasonally stronger fourth quarter.AddLife AB Corporate Events
AddLife AB AGM Approves Key Resolutions and Strategic Initiatives
May 8, 2025
At the Annual General Meeting of AddLife AB, several key resolutions were passed, including the adoption of financial statements, declaration of a SEK 0.75 per share dividend, and re-election of board members. The meeting also approved a long-term incentive program and authorized the board to manage share repurchases and transfers to optimize capital structure and facilitate future acquisitions. These decisions are expected to strengthen AddLife’s operational flexibility and strategic positioning in the market.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.